PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lonoctocog Alfa→

Lonoctocog Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1357447-52-9
Molecular formula
C7474H11438N2024O2184S78
Molecular weight
~170000 g/mol
Drug class
Recombinant single-chain coagulation factor VIIIantihaemorrhagic biologic
Mechanism of action
Replaces deficient factor VIII in the intrinsic coagulation pathway. Activated factor VIII functions as a cofactor for activated factor IX, accelerating factor X activation and supporting thrombin generation and fibrin clot formation.
Indications / reported uses
  • Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/afstyla · https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/afstyla

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Lonoctocog Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lonoctocog Alfa Permitted Daily Exposure (PDE) report (the Lonoctocog Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lonoctocog Alfa Occupational Exposure Limit (OEL) report (the Lonoctocog Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.